EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Safety, tolerability, and efficacy of adjunctive lacosamide in pediatric patients with epilepsy syndromes associated with generalized seizures: Phase 2, open‐label exploratory trial

Stéphane Auvin iD, Alexis Arzimanoglou iD, Cynthia Beller iD, Florin Floricel, Tony Daniels, Ali Bozorg iD

Epilepsia · 2023

DOI: 10.1111/epi.17741 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Epilepsia, 2023. Verfasst von Stéphane Auvin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Cité, INSERM NeuroDiderot, Paris, France. Hauptthemen laut MEDLINE: Epilepsy, Generalized, Epileptic Syndromes. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of lacosamide (LCM) (up to 12 mg/kg/day or 600 mg/day) as adjunctive therapy in pediatric patients with epilepsy syndromes associated with generalized seizures.

Methods

Phase 2, multicenter, open‐label exploratory trial (SP0966; NCT01969851; 2012‐001446‐18) of oral LCM for epilepsy syndromes associated with generalized seizures in pediatric patients ≥1 month to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epilepsy, GeneralizedEpileptic SyndromesChildFemaleHumansMaleAnticonvulsantsDouble-Blind MethodDrug Therapy, CombinationLacosamideProspective StudiesSeizuresTreatment Outcome

Stichwörter der Autor:innen

Lennox-Gastaut syndromeantiseizure medicationclinical trialelectroencephalogramgeneralized spike and wave complexespediatric epilepsy

Substanzen

AnticonvulsantsLacosamide

Autor:innen und Institutionen

  • Université Paris-Cité, INSERM NeuroDiderot, Paris, France.
  • Pediatric Neurology Department, APHP, Robert Debré University Hospital, ERN EpiCARE member, Paris, France.
  • Institut Universitaire de France (IUF), Paris, France.
  • Paediatric Clinical Epileptology and Neurophysiology Department, ERN EpiCARE member, University Hospitals of Lyon (HCL), Lyon, France.
  • Epilepsy Research Unit, San Juan de Dios Children's Hospital, ERN EpiCARE member, Barcelona, Spain.
  • UCB Pharma, Morrisville, North Carolina, USA.

ORCID-Profile: Stéphane Auvin, Alexis Arzimanoglou, Cynthia Beller, Ali Bozorg

Förderung

  • UCB Pharma

Zitieren

APA

Auvin, S., Arzimanoglou, A., Beller, C., Floricel, F., Daniels, T., & Bozorg, A. (2023). Safety, tolerability, and efficacy of adjunctive lacosamide in pediatric patients with epilepsy syndromes associated with generalized seizures: Phase 2, open‐label exploratory trial. Epilepsia. https://doi.org/10.1111/epi.17741

Vancouver

Auvin S, Arzimanoglou A, Beller C, Floricel F, Daniels T, Bozorg A. Safety, tolerability, and efficacy of adjunctive lacosamide in pediatric patients with epilepsy syndromes associated with generalized seizures: Phase 2, open‐label exploratory trial. Epilepsia. 2023. doi:10.1111/epi.17741

BibTeX
@article{Auvin2023,
  author = {Auvin, Stéphane and Arzimanoglou, Alexis and Beller, Cynthia and Floricel, Florin and Daniels, Tony and Bozorg, Ali},
  title = {Safety, tolerability, and efficacy of adjunctive lacosamide in pediatric patients with epilepsy syndromes associated with generalized seizures: Phase 2, open‐label exploratory trial},
  journal = {Epilepsia},
  year = {2023},
  doi = {10.1111/epi.17741}
}
Kostenlos starten →